Patients with >50% PDL1 expression treated using anti-PD-1 therapy showed a longer progression-free survival (PFS) period than did those treated using standard chemotherapy as the first-line treatment for NSCLC. Here, PDCD1 is linked to non-small cell lung carcinoma.